Organoid-based drug discovery platform screening therapies in patient-specific hiPSC models for rare pediatric genetic diseases.
Rosebud Biosciences develops therapies for rare genetic diseases in children by modeling disease in human induced pluripotent stem cell (hiPSC)-derived organoids carrying the patient's own gene mutations. The platform supports high-throughput screening of small molecules, RNA therapies, CRISPR, and immunotherapies using robotics and machine learning across up to 10,000 organoids per patient mutation with longitudinal live-cell imaging. The company partners with pharmaceutical companies for drug screening and conducts its own drug discovery programs in heart, liver, neural, and kidney disease. Rosebud Biosciences is a product of Rosebud Biosciences.